Healthcare / BiotechnologyNasdaqCM
$5.63
-0.15 (-2.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-58.5M · quality 73.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$321M
P/E
5.9x
↓EV/EBITDA
4.1x
↓ROE
44.7%
↑Gross Margin
41.2%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+18.1%
FCF CAGR
—
FCF margin
-1448.5%
FCF / Net income
-1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.8M · net income $71.2M · FCF $-84.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $5.8M | $5.8M | — | $3.5M | $1.4M | $3.0M | $10.0M | — | $3.0M | $837000.00 | $889000.00 | $1.0M | $925000.00 | $2.0M | $4.4M | $1.8M | $481000.00 |
| Net Income | $71.2M | $71.2M | $-63.7M | $-54.2M | $-39.7M | $-84.9M | $-84.2M | $-76.3M | $-56.7M | $-27.3M | $-21.9M | $-14.5M | $-26.8M | $4.4M | $-10.5M | $-2.5M | $-7.5M |
| EBITDA | $78.6M | $78.6M | $-56.6M | $-50.6M | $-34.4M | $-86.6M | $-76.8M | $-69.3M | $-55.8M | $-27.1M | $-23.1M | $-18.0M | $-3.1M | $-3.8M | $-3.9M | $-7.6M | $-7.5M |
| EPS | 1.01 | 1.01 | -1.55 | -2.53 | -5.53 | -21.57 | — | — | — | — | — | — | -381.50 | 76.00 | -650.00 | — | — |
| Gross Margin | 41.2% | 41.2% | — | 54.1% | 68.2% | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -1536.9% | -1536.9% | — | -1377.1% | -3200.6% | -2994.5% | -814.2% | — | -1940.2% | -3325.7% | -2686.3% | -1783.3% | -338.5% | -186.3% | -98.0% | -428.3% | -1612.7% |
| Net Margin | 1223.1% | 1223.1% | — | -1548.2% | -2807.4% | -2831.2% | -842.3% | — | -1890.3% | -3263.9% | -2460.4% | -1396.7% | -2894.9% | 217.9% | -239.1% | -137.7% | -1566.9% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.16 | 0.16 | 0.52 | 0.36 | 0.29 | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 5.89 | 5.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-84.3M | $-84.3M | $-58.5M | $-37.3M | $-43.6M | $-69.8M | $-36.4M | $-69.1M | $-48.4M | $-23.5M | $-13.5M | — | — | $-1000.00 | $-4.0M | $-7.6M | $-6.9M |
| Returns | |||||||||||||||||
| ROE | 44.7% | 44.7% | -144.7% | -365.5% | -148.3% | -200.5% | -82.1% | -42.8% | -42.3% | -16.1% | -22.1% | -21.4% | -556.0% | -30.1% | 61.7% | 14.4% | 36.2% |
| Valuation | |||||||||||||||||
| P/E | 5.93 | 5.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 4.06 | 4.06 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.34 | 2.34 | 5.61 | 8.16 | 0.91 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | 147.5% | — | -70.0% | — | — | 258.2% | -5.8% | -14.5% | 12.4% | -54.7% | -53.6% | 139.5% | 282.3% | — |
| EPS Growth | 165.2% | 165.2% | 38.7% | 54.2% | — | — | — | — | — | — | — | — | -602.0% | 111.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-20.9%
EPS terminal req.
$0.50
Spread vs growth
186.1%
5Y implied EPS CAGR
-9.8%
EPS terminal req.
$0.60
Spread vs growth
174.9%
10Y implied EPS CAGR
-0.4%
EPS terminal req.
$0.97
Spread vs growth
165.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-9.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.55 → 1.01
Residual
-9.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.